0000899243-23-006581.txt : 20230301 0000899243-23-006581.hdr.sgml : 20230301 20230301161427 ACCESSION NUMBER: 0000899243-23-006581 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230227 FILED AS OF DATE: 20230301 DATE AS OF CHANGE: 20230301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dolmetsch Ricardo CENTRAL INDEX KEY: 0001825206 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36294 FILM NUMBER: 23693672 MAIL ADDRESS: STREET 1: 113 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: uniQure N.V. CENTRAL INDEX KEY: 0001590560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP BUSINESS PHONE: 1-339-970-7000 MAIL ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP FORMER COMPANY: FORMER CONFORMED NAME: uniQure B.V. DATE OF NAME CHANGE: 20131030 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-27 0 0001590560 uniQure N.V. QURE 0001825206 Dolmetsch Ricardo C/O UNIQURE N.V. PAASHEUVELWEG 25A AMSTERDAM P7 11058BP NETHERLANDS 0 1 0 0 President, R&D Ordinary Shares 2023-02-27 4 S 0 6944 19.58 D 170082 D As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. The price reported in Column 4 is a weighted average price. 6,824 of the shares were sold in multiple transactions at prices ranging from $19.21 to $19.81, 63 of the shares were sold at $20.86 and 57 of the shares were sold at $20.87. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Christian Klemt, Attorney-in-Fact 2023-03-01